Tissue Regenix Group PLC Notice of Preliminary Results (7111V)
April 20 2016 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 7111V
Tissue Regenix Group PLC
20 April 2016
Tissue Regenix Group plc
Notice of Preliminary Results
Leeds, 20th April 2016 - Tissue Regenix Group plc (AIM:TRX)
("Tissue Regenix" or "The Group"), the regenerative medical devices
company, announces that it will publish its unaudited preliminary
results for the year ended 31(st) January 2016, on Monday 23(rd)
May 2016.
A results presentation will be held on the morning of the 23(rd)
May in London, with corporate and financial updates from CEO Antony
Odell, and CFO, Ian Jefferson, as well as guest speaker Dr
Francisco da Costa from The Groups research partner, Pontifícia
Universidade Católica do Paraná, Curitiba, Brazil.
If you would like to attend, or for further information, please
contact c.pearson@tissueregenix.com
Tissue Regenix Group plc Tel: 0330
Caitlin Pearson Corporate Communications 430 3073
Officer
========================================== ===========
Jefferies International Ltd Tel: 020
Simon Hardy / Harry Nicholas 7029 8000
========================================== ===========
Tulchan Communications Tel: 020
James Macey-White / Matt Low 7353 4200
========================================== ===========
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOREANLNFAPKEFF
(END) Dow Jones Newswires
April 20, 2016 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2023 to Aug 2024